Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4HDR2
|
|||
| Drug Name |
LVGN6051
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Lyvgen Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | Activator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04130542) Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy. U.S. National Institutes of Health. | |||
| REF 2 | Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.